The questions I had Ms. Chen of Collins Stewart ask a couple of weeks ago pretty much address this question.
I disagree, RockRat. Where in your list of questions did you ask about the possibility that Teva’s Lovenox might be manufactured by another company and that Teva might effectively be nothing more than a marketing arm in this instance?
So not sure why this horse is being beaten again as if it's novel.
Because this is a novel line of inquiry and perhaps a very consequential one for MNTA investors.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”